Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


0.00 (0.00%)

Market Cap$3,771,052,480

02/11/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results 02/09/16

Read more

Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda 02/04/16

Read more


4th Quarter & Year 2015 Financial Results Conference Call02/09/16 4:30 p.m. ETView event34th Annual J.P. Morgan Healthcare Conference01/11/16 2:30 p.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources